Moreover, IL4 treatment results in decreased phosphorylation of some MAP kinases usually hyperactivated during cancer cachexia and shown to play a role in promoting muscle protein degradation.4, 7 This last observation is as well supported by lower levels of p62 accumulation in IL4‐treated than IL4‐untreated C26 hosts. This evidence concerns the gene IL4 and cancer.